BRITAJECT

This brand name is authorized in Lithuania

Active ingredients

The drug BRITAJECT contains one active pharmaceutical ingredient (API):

1 Apomorphine
UNII F39049Y068 - APOMORPHINE HYDROCHLORIDE

Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites.

Read about Apomorphine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N04BC07 Apomorphine N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BC Dopamine agonists
Discover more medicines within N04BC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1057523, 1057524, 1058357, 1058358, 1066111, 1066112, 1066113, 1066114, 1067358

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈